Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: OCL004
MIFTS: 32

Ocular Hyperemia

Categories: Eye diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Ocular Hyperemia

About this section

MalaCards integrated aliases for Ocular Hyperemia:

Name: Ocular Hyperemia 12 15 73
Hyperemia of Conjunctiva 12
Hyperemia Eye 12

Classifications:

MalaCards categories:
Anatomical: Eye diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:1248
SNOMED-CT 68 76849009
UMLS 73 C0155169
Sources

Summaries for Ocular Hyperemia

About this section
MalaCards based summary : Ocular Hyperemia, also known as hyperemia of conjunctiva, is related to adenoid hypertrophy and acid-labile subunit deficiency, and has symptoms including redness of eye An important gene associated with Ocular Hyperemia is TRPV1 (Transient Receptor Potential Cation Channel Subfamily V Member 1), and among its related pathways/superpathways are Pathways in cancer and Epstein-Barr virus infection. The drugs Bimatoprost and Timolol have been mentioned in the context of this disorder. Affiliated tissues include eye, and related phenotypes are homeostasis/metabolism and behavior/neurological

Sources

Related Diseases for Ocular Hyperemia

About this section

Diseases related to Ocular Hyperemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 14)
# Related Disease Score Top Affiliating Genes
1 adenoid hypertrophy 10.2 SOD1 TRPV1
2 acid-labile subunit deficiency 10.1 IGF2 IGFBP3
3 red-green color blindness 10.1 IGF2 RPE65
4 complete androgen insensitivity syndrome 10.1 IGF2 IGFBP3
5 fetal macrosomia 10.1 IGF2 IGFBP3
6 laron syndrome 10.0 IGF2 IGFBP3
7 hereditary wilms' tumor 10.0 ALK IGF2
8 prader-willi syndrome 10.0 EHMT2 IGF2 IGFBP3
9 nervous system disease 9.9 IFNB1 SOD1 TRPV1
10 japanese encephalitis 9.9 IFNB1 SOD1
11 central nervous system disease 9.9 IFNB1 SLC6A2 SOD1 TRPV1
12 transient hypogammaglobulinemia of infancy 9.8 ALK CD40
13 immune system disease 9.7 CD40 IFNB1 PRTN3 TRPV1
14 ewing sarcoma 9.5 ALK IFNB1 IGF2 IGFBP3

Graphical network of the top 20 diseases related to Ocular Hyperemia:



Diseases related to Ocular Hyperemia
Sources

Symptoms & Phenotypes for Ocular Hyperemia

About this section

UMLS symptoms related to Ocular Hyperemia:


redness of eye

MGI Mouse Phenotypes related to Ocular Hyperemia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.14 ALK BCL2L11 CD40 IFNB1 IGF2 IGFBP3
2 behavior/neurological MP:0005386 10.13 ALK EHMT2 IGF2 IGFBP3 PTGER3 RPE65
3 immune system MP:0005387 10.11 BCL2L11 CD40 EFS EHMT2 IFNB1 IGF2
4 hematopoietic system MP:0005397 10.09 BCL2L11 CD40 EFS EHMT2 IFNB1 IGF2
5 endocrine/exocrine gland MP:0005379 10 ALK BCL2L11 CD40 EHMT2 IGF2 IGFBP3
6 integument MP:0010771 9.92 ALK BCL2L11 IGF2 IGFBP3 PTGER3 SLC6A2
7 nervous system MP:0003631 9.85 ALK BCL2L11 CD40 EHMT2 IFNB1 IGF2
8 neoplasm MP:0002006 9.65 ALK BCL2L11 IFNB1 SOD1 TRPV1
9 pigmentation MP:0001186 9.26 ALK BCL2L11 IGFBP3 RPE65
10 renal/urinary system MP:0005367 9.17 BCL2L11 CD40 EFS IGF2 IGFBP3 PTGER3
Sources

Drugs & Therapeutics for Ocular Hyperemia

About this section

Drugs for Ocular Hyperemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 60)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bimatoprost Approved, Investigational Phase 4 155206-00-1 5311027
2
Timolol Approved Phase 4 26839-75-8 33624 5478
3
Travoprost Approved Phase 4,Phase 3 157283-68-6 5282226
4
Latanoprost Approved, Investigational Phase 4 130209-82-4 5311221 5282380
5
Maleic acid Experimental Phase 4 110-16-7 444266
6 Antihypertensive Agents Phase 4,Phase 3,Phase 2
7 Ophthalmic Solutions Phase 4,Phase 2,Phase 3
8 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3
9 Adrenergic Antagonists Phase 4,Phase 2
10 Adrenergic beta-Antagonists Phase 4
11 Anti-Arrhythmia Agents Phase 4
12 Adrenergic Agents Phase 4,Phase 3,Phase 2,Not Applicable
13 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
14 Anti-Infective Agents, Local Phase 4
15 Benzalkonium Compounds Phase 4
16 Anti-Infective Agents Phase 4
17
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
18
Pseudoephedrine Approved Phase 3 90-82-4 7028
19
Loratadine Approved, Investigational Phase 3 79794-75-5 3957
20
Fexofenadine Approved, Investigational Phase 3 83799-24-0 3348
21
Ephedrine Approved Phase 3 299-42-3 9294
22
Adalimumab Approved Phase 2, Phase 3 331731-18-1 16219006
23
Histamine Phosphate Phase 3 51-74-1 65513
24 Histamine H1 Antagonists, Non-Sedating Phase 3
25 Peripheral Nervous System Agents Phase 3,Not Applicable
26 Analgesics Phase 3
27 Anti-Allergic Agents Phase 3
28 Anti-Inflammatory Agents Phase 3,Phase 2
29 Anti-Inflammatory Agents, Non-Steroidal Phase 3
30 Antirheumatic Agents Phase 3,Phase 2
31 Analgesics, Non-Narcotic Phase 3
32 Olopatadine Hydrochloride Phase 3
33 Histamine H1 Antagonists Phase 3
34 Histamine Antagonists Phase 3
35 Vasoconstrictor Agents Phase 3,Not Applicable
36 Sympathomimetics Phase 3,Not Applicable
37 Anti-Asthmatic Agents Phase 3,Not Applicable
38 Nasal Decongestants Phase 3
39 Autonomic Agents Phase 3,Not Applicable
40 Dermatologic Agents Phase 3
41 Central Nervous System Stimulants Phase 3
42 Antipruritics Phase 3
43 Respiratory System Agents Phase 3,Not Applicable
44 Bronchodilator Agents Phase 3,Not Applicable
45 Antibodies, Monoclonal Phase 2, Phase 3
46 Antibodies Phase 2, Phase 3
47 Immunoglobulins Phase 2, Phase 3
48 Immunologic Factors Phase 2, Phase 3
49
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
50
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743

Interventional clinical trials:

(show all 27)
# Name Status NCT ID Phase Drugs
1 A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH) Completed NCT01594970 Phase 4 Bimatoprost 0.01%
2 A Study of LUMIGAN® RC in the Clinical Setting Completed NCT01833741 Phase 4 Bimatoprost 0.01%
3 Efficacy of Changing to DUOTRAV® From Prior Therapy Completed NCT01327599 Phase 4 Travoprost 0.004%+Timolol 0.5% ophthalmic solution
4 An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN® Completed NCT01664039 Phase 4 Travoprost 0.004% ophthalmic solution;Bimatoprost 0.01% ophthalmic solution
5 A Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Glaucoma Recruiting NCT02792803 Phase 4 Xalatan;Apo-Latanoprost;Co-Latanoprost
6 Efficacy of Changing to DuoTrav® (Travoprost 0.004%/Timolol 0.5% BAK-Free Fixed Combination) From Prior Therapy Terminated NCT01514721 Phase 4 Travoprost/Timolol Maleate BAK-Free Fixed Combination
7 Phase II/III Study of the Efficacy and Safety of MacuCLEAR MC-1101 in Treating DryAge-Related Macular Degeneration Unknown status NCT02127463 Phase 2, Phase 3 MC-1101;MC-1101 Vehicle
8 ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis Completed NCT03494504 Phase 3 Reproxalap Ophthalmic Solution (0.25%);Reproxalap Ophthalmic Solution (0.5%);Vehicle Ophthalmic Solution
9 AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic Conjunctivitis Completed NCT02161146 Phase 3 AGN-229666;Vehicle to AGN-229666;Olopatadine
10 Effectiveness of Two Preparations of Loratadine + Pseudoephedrine in Patients With Perennial Allergic Rhinitis. Completed NCT01228630 Phase 3 Cloratadd-D;Allegra-D
11 An Open-Label, Long-Term Study With AL-4943A Ophthalmic Solution, 0.2% in Patients With Allergic Conjunctivitis Completed NCT01037179 Phase 3 Olopatadine Hydrochloride Ophthalmic Solution, 0.2%
12 Effect of Adalimumab for the Treatment of Uveitis in Juvenile Idiopathic Arthritis Completed NCT01385826 Phase 2, Phase 3 Anti-tumor necrosis factor alpha monoclonal antibody;placebo
13 OTX-16-002: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-TP in Subjects With Open-Angle Glaucoma and Ocular Hypertension Recruiting NCT02914509 Phase 3 Travoprost
14 Efficacy and Safety Study of MC-1101 1% TID in the Treatment of Nonexudative Age-Related Macular Degeneration Terminated NCT01601483 Phase 2, Phase 3 MC-1101;MC-1101 Vehicle
15 A Study to Assess the Effect of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Chronic Angle-closure Glaucoma Unknown status NCT02152774 Phase 2 Rho-Kinase Inhibitor
16 A Compassionate Case Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Glaucoma Patients With Uncontrolled Intraocular Pressure to Avoid Surgical Intervention Unknown status NCT02174991 Phase 2 Rho-Kinase Inhibitor (AR-12286)
17 A Study to Assess the Effect of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Uncontrolled Advanced Glaucoma With Prior Failed Trabeculectomy or Tube Shunt Unknown status NCT02173223 Phase 2 Rho-Kinase Inhibitor
18 Phase 2/3 Study Evaluating Efficacy and Safety of OTX-DP for Treatment of Chronic Allergic Conjunctivitis Completed NCT02062905 Phase 2 OTX-DP treatment
19 A Study of ADX-102 in Subjects With Allergic Conjunctivitis Completed NCT03012165 Phase 2 ADX-102 Ophthalmic Drops (0.5%);ADX-102 Ophthalmic Drops (0.1%);Vehicle of ADX-102 Ophthalmic Drops
20 The Safety and Efficacy of Phentolamine Mesylate Ophthalmic Solution in Subjects With Severe Night Vision Complaints Completed NCT01703559 Phase 2 Phentolamine mesylate ophthalmic solution
21 Effectiveness of PR013 Topical Ophthalmic Drops Compared to Vehicle for the Treatment of Allergic Conjunctivitis Recruiting NCT03368339 Phase 2 PR013 (0.045%);PR013 (0.06%);Placebo
22 Consolidation Therapy With Hu3S193 for Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer Terminated NCT01137071 Phase 2
23 A Study of Bimatoprost 0.01% in the Clinical Setting Completed NCT01814761 Bimatoprost 0.01%
24 Non Interventional Study With Primary Open Angle Glaucoma and/or Ocular Hypertension Patients Treated With Xalacom® After Failure of Previous Antiglaucoma Therapy. Completed NCT00801437 Xalacom
25 Food Allergy Diagnostic Test Response to Previous Oral Challenge Response Completed NCT03693456 Not Applicable
26 EyeBag Effectiveness in Meibomian Gland Dysfunction Completed NCT01870180 Not Applicable
27 Long-Term Non-Interventional Latanoprost Study Completed NCT01265719

Search NIH Clinical Center for Ocular Hyperemia

Sources

Genetic Tests for Ocular Hyperemia

About this section
Sources

Anatomical Context for Ocular Hyperemia

About this section

MalaCards organs/tissues related to Ocular Hyperemia:

41
Eye
Sources

Publications for Ocular Hyperemia

About this section

Articles related to Ocular Hyperemia:

# Title Authors Year
1
Seeing red: guiding the management of ocular hyperemia. ( 18528197 )
2008
2
External ocular hyperemia: a quantifiable indicator of spacecraft air quality. ( 8725467 )
1996
3
Automatic quantitative measurement of ocular hyperemia. ( 8974839 )
1995
4
Role of nitric oxide in PGF2 alpha-induced ocular hyperemia. ( 7532135 )
1994
5
Degeneration release of norepinephrine causes transient ocular hyperemia mediated by prostaglandins. ( 4692259 )
1973
Sources

Variations for Ocular Hyperemia

About this section
Sources

Expression for Ocular Hyperemia

About this section
Search GEO for disease gene expression data for Ocular Hyperemia.
Sources

Pathways for Ocular Hyperemia

About this section

Pathways related to Ocular Hyperemia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Pathways in cancer 37
11.98 ALK BCL2L11 IGF2 PTGER3
2
Epstein-Barr virus infection 37
11.64 BCL2L11 CD40 IFNB1
3
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) 66
9.95 IGF2 IGFBP3
Sources

GO Terms for Ocular Hyperemia

About this section

Biological processes related to Ocular Hyperemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of protein phosphorylation GO:0001934 9.58 ALK CD40 IGF2
2 positive regulation of apoptotic process GO:0043065 9.56 BCL2L11 IGFBP3 SOD1 TRPV1
3 B cell proliferation GO:0042100 9.43 CD40 IFNB1
4 response to pain GO:0048265 9.37 SLC6A2 TRPV1
5 cellular response to ATP GO:0071318 9.32 SOD1 TRPV1
6 myeloid cell homeostasis GO:0002262 9.16 BCL2L11 SOD1
7 regulation of organ growth GO:0046620 8.96 BCL2L11 SOD1
8 response to nutrient levels GO:0031667 8.8 CD40 EHMT2 SOD1
Sources

Sources for Ocular Hyperemia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....